The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase I study of ruxolitinib in children with relapsed/refractory solid tumors, leukemias, or myeloproliferative neoplasms: A Children's Oncology Group Phase I Consortium study (ADVL1011).
Sarah K. Tasian
No relevant relationships to disclose
Mignon L. Loh
No relevant relationships to disclose
Karen R. Rabin
No relevant relationships to disclose
Patrick Andrew Brown
No relevant relationships to disclose
Charlotte H. Ahern
No relevant relationships to disclose
Brenda Weigel
No relevant relationships to disclose
Susan Blaney
No relevant relationships to disclose